Dashboard
Manage Tickers

NAMSNewAmsterdam Pharma Co N.V.

Nasdaq newamsterdampharma.com


$ 18.35 $ -0.84 (-4.38 %)    

Monday, 17-Jun-2024 14:22:29 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 485.92 $ 5.96 (1.24 %)
DIA $ 388.52 $ 3.46 (0.9 %)
SPY $ 547.69 $ 5.61 (1.04 %)
TLT $ 93.68 $ -0.18 (-0.19 %)
GLD $ 214.41 $ -0.47 (-0.22 %)
$ 19.19
$ 19.49
$ 0.00 x 0
$ 0.00 x 0
$ 18.13 - $ 19.49
$ 5.63 - $ 26.35
75,625
na
1.73B
$ 1.75
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

newamsterdam-pharma-announces-issuance-of-composition-of-matter-patent-for-obicetrapib-by-the-uspto
NewAmsterdam Pharma Announces Issuance Of ...
06/11/2024 12:21:43

-- New patent extends patent term for obicetrapib until July 2043 --NAARDEN, the Netherlands and MIAMI, June 11, 2024 (GLOBE NE...

rbc-capital-reiterates-outperform-on-newamsterdam-pharma-maintains-31-price-target
RBC Capital Reiterates Outperform on NewAm...
06/07/2024 14:39:06

RBC Capital analyst Leonid Timashev reiterates NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform and maintains $31 price t...

newamsterdam-pharma-presents-new-clinical-and-preclinical-data-on-obicetrapibs-impact-on-key-risk-factors-for-cardiovascular-disease-at-upcoming-medical-meetings
NewAmsterdam Pharma Presents New Clinical ...
05/21/2024 12:25:41

-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib's impact o...

td-cowen-initiates-coverage-on-newamsterdam-pharma-with-buy-rating
TD Cowen Initiates Coverage On NewAmsterda...
05/15/2024 17:12:04

TD Cowen analyst Tyler Van Buren initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating.

newamsterdam-pharma-q1-eps-106-vs-051-yoy
NewAmsterdam Pharma Q1 EPS $(1.06) Vs $(0....
05/09/2024 13:04:29

First Quarter Financial ResultsCash Position: As of March 31, 2024, NewAmsterdam recorded cash of $481.1 million, compared to $...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
04/29/2024 20:31:14

newamsterdam-pharma-enrolls-over-9000-patients-in-pivotal-phase-3-prevail-global-cardiovascular-outcome-trial-evaluating-the-effect-of-obicetrapib-in-patients-with-established-atherosclerotic-cardiovascular-disease
Newamsterdam Pharma Enrolls Over 9,000 Pat...
04/09/2024 12:54:03

newamsterdam-pharma-to-present-new-analysis-from-the-phase-2-rose2-trial-evaluating-obicetrapib-in-combination-with-ezetimibe-at-2024-american-college-of-cardiology-congress
NewAmsterdam Pharma To Present New Analysi...
03/25/2024 12:21:22

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin me...

scotiabank-initiates-coverage-on-newamsterdam-pharma-with-sector-outperform-rating-announces-price-target-of-35
Scotiabank Initiates Coverage On NewAmster...
03/14/2024 11:40:42

Scotiabank analyst George Farmer initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform rating and...

scotiabank-initiates-coverage-on-newamsterdam-pharma-with-sector-outperform-rating-announces-price-target-of-35
Scotiabank Initiates Coverage On NewAmster...
03/13/2024 21:22:42

Scotiabank analyst George Farmer initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform rating and...

newamsterdam-pharma-announced-dosing-of-the-first-patient-and-initiation-of-tandem-phase-3-trial-to-evaluate-obicetrapib-and-ezetimibe-fdc-in-adult-patients-with-heterozygous-familial-hypercholesterolemia-andor-atherosclerotic-cardiovascular-disease
NewAmsterdam Pharma Announced Dosing Of Th...
03/12/2024 12:13:38

rbc-capital-maintains-outperform-on-newamsterdam-pharma-raises-price-target-to-31
RBC Capital Maintains Outperform on NewAms...
02/29/2024 17:09:49

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform and raises the price targe...

newamsterdam-pharma-reports-full-year-2023-eps-215-vs-119-yoy-revenue-141m-vs-1027m-yoy
NewAmsterdam Pharma Reports Full Year 2023...
02/28/2024 13:14:02

Full Year 2023 Financial ResultsCash Position: As of December 31, 2023, NewAmsterdam recorded cash of $340.5 million, compared ...

newamsterdam-pharma-prices-1753m-public-offering-of-ordinary-shares-and-pre-funded-warrants
NewAmsterdam Pharma Prices $175.3M Public ...
02/14/2024 07:40:15

NewAmsterdam Pharma announced the pricing of the previously announced underwritten public offering of (i) 4,488,159 of the Comp...

newamsterdam-pharma-reveals-commencement-of-public-offering-of-ordinary-shares-and-pre-funded-warrants-no-terms-disclosed
NewAmsterdam Pharma Reveals Commencement O...
02/13/2024 21:03:33

In addition, the Company expects to grant the underwriters a 30-day option to purchase a number of additional shares not to exc...

why-transcode-therapeutics-shares-are-trading-lower-by-over-24-here-are-other-stocks-moving-in-fridays-mid-day-session
Why TransCode Therapeutics Shares Are Trad...
01/19/2024 18:05:18

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,...

world-acceptance-posts-upbeat-earnings-joins-kaman-spirit-airlines-and-other-big-stocks-moving-higher-on-friday
World Acceptance Posts Upbeat Earnings, Jo...
01/19/2024 15:20:42

U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of World Acceptance Corporatio...

guggenheim-initiates-coverage-on-newamsterdam-pharma-with-buy-rating-announces-price-target-of-30
Guggenheim Initiates Coverage On NewAmster...
01/18/2024 12:11:09

Guggenheim analyst Debjit Chattopadhyay initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating and announ...

piper-sandler-initiates-coverage-on-newamsterdam-pharma-with-overweight-rating-announces-price-target-of-37
Piper Sandler Initiates Coverage On NewAms...
01/16/2024 20:26:14

Piper Sandler analyst Yasmeen Rahimi initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Overweight rating and an...

cholesterol-player-newamsterdam-pharmas-obicetrapib-is-a-potential-blockbuster-in-cardiovascular-market-bullish-analyst-says
Cholesterol Player NewAmsterdam Pharma's O...
01/16/2024 19:48:08

Piper Sandler's coverage on NewAmsterdam Pharma and its clinical-stage therapy, Obicetrapib, a potent CETP inhibitor target...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)